← Back to Search

Brachytherapy

High vs Low Dose Rate Brachytherapy for Prostate Cancer

N/A
Recruiting
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Prior or current bleeding diathesis
Previous androgen deprivation therapy (ADT)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing two different types of radiation therapy to see which is better at treating prostate cancer.

Who is the study for?
Men over 18 with recently diagnosed low or intermediate risk prostate cancer, who haven't had hormone therapy, surgery, radiation, or chemotherapy for it. They should be fit for brachytherapy, have a prostate size ≤60 cc and an AUA score ≤20. Participants must complete questionnaires in English/French and agree to prevent pregnancy during the trial.
What is being tested?
The study compares two types of radiation treatments: High Dose Rate (HDR) brachytherapy with a new higher dose against Low Dose Rate (seed) brachytherapy. It aims to see which is better at controlling cancer and assesses short/long-term side effects.
What are the potential side effects?
Possible side effects include discomfort or pain from the procedure, urinary issues like frequency or urgency, bowel changes such as diarrhea, erectile dysfunction, and rare risks associated with anesthesia.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of unusual bleeding or clotting.
Select...
I have undergone hormone therapy for cancer.
Select...
I have had major surgery, radiation, chemotherapy, TURP, or cryosurgery for prostate cancer.
Select...
My cancer has spread to other parts of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Brachytherapy
Secondary study objectives
Economic Analysis
Number and severity of adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Arm 3 HDRActive Control1 Intervention
High Dose Rate brachytherapy: 27 Gy in 2 fractions
Group II: Arm 1 LDRActive Control1 Intervention
Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy

Find a Location

Who is running the clinical trial?

Canadian Cancer Trials GroupLead Sponsor
131 Previous Clinical Trials
69,315 Total Patients Enrolled
10 Trials studying Prostate Cancer
6,903 Patients Enrolled for Prostate Cancer
Gerard MortonStudy ChairSunnybrook Health Sciences, Toronto ON
1 Previous Clinical Trials
55 Total Patients Enrolled
1 Trials studying Prostate Cancer
55 Patients Enrolled for Prostate Cancer
Eric VigneaultStudy ChairHotel Dieu de Quebec, Montreal, QC
1 Previous Clinical Trials
57 Total Patients Enrolled
1 Trials studying Prostate Cancer
57 Patients Enrolled for Prostate Cancer

Media Library

High dose rate brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02960087 — N/A
Prostate Cancer Research Study Groups: Arm 3 HDR, Arm 1 LDR
Prostate Cancer Clinical Trial 2023: High dose rate brachytherapy Highlights & Side Effects. Trial Name: NCT02960087 — N/A
High dose rate brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02960087 — N/A
~77 spots leftby Sep 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top